3DBio Therapeutics, a biotech company in Queens, said it had for the first time used 3-D printing to make a…
NEW POST
NEW POST
3DBio Therapeutics, a biotech company in Queens, said it had for the first time used 3-D printing to make a…
NEW POST
FIZE Medical Ltd. FIZE an innovative provider of data derived from monitoring real-time urine output, announced today the closing of $4 million Series A-1 funding.
SPAC season is back as Arbor Rapha Capital Bioholdings, a blank-check company, lands on the public markets today to raise $150 million for a future biopharma merger. By Kyle LaHucik | Oct 29, 2021 10:15am | FierceBiotech
New deal with Takeda could mean up to $3.6 billion in milestone payments.
Demeetra Agbio, a Rapha portfolio company was recently featured in an article in the leading industry publication, CRISPR News MEDICINE. Demeetra AgBio, headquartered in Kentucky, is pioneering a unique genome-editing technology called Cas-CLOVER. Applications include plant-based drug development, enhanced bioprocessing for human and animal health, and engineering of crops and agricultural animals for improved traits. The author, Karen O’Hanlon Cohrt, spoke with Demeetra’s CEO Jack Crawford to hear more about Cas-CLOVER and its potential within human health and medicine.
MIAMI, June 25, 2020 /PRNewswire/ — Rapha Capital Management, LLC (https://raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment XI,…
MIAMI, May 4, 2020 /PRNewswire/ — Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment…
MIAMI, Oct. 2, 2019 /PRNewswire/ — Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment…
MIAMI, April 22, 2019 /PRNewswire/ — Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, and their associated entities…
Rapha Capital Management, LLC is providing this website for informational purposes only. Nothing on this website is intended to constitute, or should be deemed to be, financial advisory, legal, tax, accounting or other professional advice to you or any other party; be an opinion of the appropriateness or suitability of any investment; or constitute an offer to sell or solicitation of an offer to buy any security or investment. This website and its content (collectively, “Content”) is intended for general informational purposes only and should not be acted upon without first obtaining financial advisory, legal, tax, accounting or other professional advice from your consultant or other professional with respect to your own personal investment objectives, financial circumstances and needs. Nothing on the Site shall be considered a recommendation or solicitation to buy or an offer to sell a security to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Any investment decisions you may make on the basis of any information found on this web site is your sole responsibility. Prior to making any investment or hiring any investment manager you should consult with a professional financial advisor, legal and tax advisor to assist in due diligence as may be appropriate and determining the appropriateness of the risk associated with a particular investment. In no event shall Rapha Capital Management, LLC be responsible or liable for the correctness of any such material or for any damage or lost opportunities resulting from use of these data.